Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD): Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF: Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD): Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD): primary endpoint results, effect estimate with confidence interval, sample-size…
- Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL: Complete Statistical AnalysisIndependent statistical analysis of Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02904902).
- Open-label Study of ASP2151 in Herpes Simplex Patients: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of ASP2151 in Herpes Simplex Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02209324).
- Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213): Complete Statistical AnalysisIndependent statistical analysis of Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A: primary endpoint results, effect estimate with…
- Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism: primary endpoint results, effect estimate…
- Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias: primary endpoint results, effect estimate with confidence interval,…
- Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies – (FIGHT-101): Complete Statistical AnalysisIndependent statistical analysis of Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas: Complete Statistical AnalysisIndependent statistical analysis of Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country: Complete Statistical AnalysisIndependent statistical analysis of Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD): Complete Statistical AnalysisIndependent statistical analysis of Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD): primary endpoint results, effect estimate with confidence interval, sample-size…
- Open-Labeled PK-PD Studies of Metoprolol ER: Complete Statistical AnalysisIndependent statistical analysis of Open-Labeled PK-PD Studies of Metoprolol ER: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02417246).
- Open, Prosp, Rand. Invest. Evaluating Pain With Mepitel One vs.Bridal Veil and Staples on Split Thickness Skin Grafts: Complete Statistical AnalysisIndependent statistical analysis of Open, Prosp, Rand. Invest. Evaluating Pain With Mepitel One vs.Bridal Veil and Staples on Split Thickness Skin Grafts: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- OPERAIndependent statistical analysis of A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- OPERA IIIndependent statistical analysis of A Study To Monitor Long-Term Treatment With PF-00547659: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01298492).
- Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients: Complete Statistical AnalysisIndependent statistical analysis of Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- OPESIIndependent statistical analysis of Orthodontic Patient Experience of Intraoral Scans Versus Alginate Impressions: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05194956).
- Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL): Complete Statistical AnalysisIndependent statistical analysis of Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01298219).
- OPSISIndependent statistical analysis of Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia: primary endpoint results, effect estimate with confidence interval,…
- OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission: Complete Statistical AnalysisIndependent statistical analysis of OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission: primary endpoint results,…
- OpT2miseIndependent statistical analysis of OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Optic Nerve Head Structural Response to IOP Elevation in Patients With Keratoconus: Complete Statistical AnalysisIndependent statistical analysis of Optic Nerve Head Structural Response to IOP Elevation in Patients With Keratoconus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Optical Frequency Domain Imaging (OFDI) Surveillance and Image Guided Biopsy of the Esophagus: Complete Statistical AnalysisIndependent statistical analysis of Optical Frequency Domain Imaging (OFDI) Surveillance and Image Guided Biopsy of the Esophagus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- OPTIMALIndependent statistical analysis of Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subjects With Newly or Recently Diagnosed Partial Epilepsy: primary endpoint results, effect estimate with confidence interval, sample-size…
- Optimal Bupivacaine Dose for Initiation of Labor Epidural Techniques: Complete Statistical AnalysisIndependent statistical analysis of Optimal Bupivacaine Dose for Initiation of Labor Epidural Techniques: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04814537).
- Optimal Care of Complicated Appendicitis: Complete Statistical AnalysisIndependent statistical analysis of Optimal Care of Complicated Appendicitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03159754).
- Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda: Complete Statistical AnalysisIndependent statistical analysis of Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Optimal Dosing of Ketamine for Procedural Sedation and Analgesia in Children: Complete Statistical AnalysisIndependent statistical analysis of Optimal Dosing of Ketamine for Procedural Sedation and Analgesia in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Optimal Duration of Indwelling Urinary Catheter Following Pelvic Surgery: Complete Statistical AnalysisIndependent statistical analysis of Optimal Duration of Indwelling Urinary Catheter Following Pelvic Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01923129).
- Optimal Fluid Resuscitation for Trauma Patients: Complete Statistical AnalysisIndependent statistical analysis of Optimal Fluid Resuscitation for Trauma Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00527098).
- OPTIMenIndependent statistical analysis of Optimizing Protein Intake in Older Americans With Mobility Limitations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01275365).
- Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe: Complete Statistical AnalysisIndependent statistical analysis of Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- OPTIMISMMIndependent statistical analysis of Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Optimization of a New Adaptive Intervention to Increase COVID-19 Testing: Complete Statistical AnalysisIndependent statistical analysis of Optimization of a New Adaptive Intervention to Increase COVID-19 Testing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04757298).
- Optimization of Synvisc-One for Knee OA: Complete Statistical AnalysisIndependent statistical analysis of Optimization of Synvisc-One for Knee OA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02029703).
- OPTIMIZE-1Independent statistical analysis of A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery: primary endpoint…
- OPTIMIZE-2Independent statistical analysis of A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery: primary…